We are monitoring the impact of COVID-19 on Europe Infectious Disease Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1247
Share on
Share on

Europe Infectious Disease Therapeutics Market Research Report – Segmented By Mode Of Treatment, Target Organism, Infection Type, Distribution Channels and Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) - Industry Analysis, Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1247
Pages: 145

Europe Infectious Disease Therapeutics Market Size (2021 to 2026)

The size of the Europe Infectious Disease Therapeutics Market is predicted to be worth USD 40.97 billion by 2026 from USD 29.24 billion in 2021, growing at a CAGR of 6.98% during the forecast period.

Rising investments to discover new medications to treat infectious diseases, Government and private organizations are heavily investing in the healthcare sector, and an increase in the number of efforts to promote awareness about these disorders are projected to drive the Europe Infectious Disease Therapeutics market during the forecast period. Infectious disease treatments are being used more frequently as the prevalence of infectious diseases rises. Other factors driving the growth of the infectious diseases therapeutics market include the increased usage of direct-acting antivirals, an increase in the elderly population, and rising healthcare spending. One of the key factors for market growth during the forecast period is the rising incidence of infectious illnesses such as tuberculosis, AIDS, and others throughout the region.

Additionally, infectious disease treatments are likely to see a rise in demand as more patents expire and generic medicines enter the market due to their low pricing. The availability of reimbursement for diagnosis and treatment of various infections and free medicine distribution by manufacturers in areas where these diseases are prevalent will likely propel the European Infectious Disease Therapeutics market further. The emergence of interferon-free regimens and increased awareness programs are two trends in the infectious diseases treatments industry. Advances in the rapid diagnosis of many infectious diseases, which allow for earlier and faster diagnosis, have a significant influence on the medical result of disease treatment. Advanced technologies utilized in fast diagnostics of infectious diseases, such as lateral flow, agglutination tests, and solid phase, are combined with novel characteristics such as mobility of portable devices to provide a viable approach.

During the forecast period, the Europe Infectious Disease Therapeutics market is likely to be restrained by a low penetration rate of anti-infective and the availability of a significant number of counterfeit medications. In this nation, limited treatment adoption and low per capita healthcare expenditure may limit market growth throughout the forecast period. Furthermore, lack of awareness regarding treatments for disorders, poor treatment adoption, and lack of funding for certain infectious illnesses are likely to limit the growth of the infectious disease therapeutics market during the forecast period.

Generic erosion is one of the key issues restricting the Europe Infectious Disease Therapeutics market's growth. The infectious diseases therapeutics industry may face a challenge when patents on infectious disease medicines expire.

This research report on the European Infectious Disease Therapeutics Market has been segmented & sub-segmented into the following categories:

By Mode of Treatment:

  • Drugs     
  • Vaccines    

By Target Organism:

  • Antibacterial      
  • Antifungal
  • Antiviral  
  • Antiparasite      
  • others     

By Infection type: 

  • Bacterial  
  • Viral      
  • Fungal    
  • Parasitic  
  • Others    

By Distribution Channels: 

  • Hospitals  
  • Clinics     
  • Others

By Country:

  • United Kingdom
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Rest of Europe

Regional Analysis:

Europe is the world's second-largest market for infectious disease therapeutics. The European market is driven by high healthcare spending, government funding for research and development, and a large patient population. In the worldwide infectious diseases therapeutics market, Europe is anticipated to develop rapidly over the next five years. The rising need for efficient and quick diagnostic testing, an increase in the number of methods used by market participants to extend their geographic reach in this area, and government organizations’ involvement in reducing illness burden are likely to fuel market growth.

KEY MARKET PLAYERS:

Companies that are playing an influential role in the European Infectious disease Therapeutics Market profiled in this report are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Pfizer, Achillion Pharmaceuticals, Novartis, AbbVie, Astellas Pharma, AstraZeneca, Auritec Pharmaceuticals, Bayer, Bristol-Myers Squibb, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals, Mitsubishi Tanabe Pharma, pSivida, Sanofi.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Mode of Treatment                

                                5.1.1 Introduction           

                                5.1.2 Drugs        

                                                5.1.2.1 Oral Administration

                                                5.1.2.2 Topical

                                                5.1.2.3 Injections

                                                5.1.2.4 Others

                                5.1.3 Vaccines  

                                5.1.4 Y-o-Y Growth Analysis, By Mode of treatment         

                                5.1.5 Market Attractiveness Analysis, By Mode of treatment        

                                5.1.6 Market Share Analysis, By Mode of treatment         

                5.2 Target Organism                      

                                5.2.1 Introduction           

                                5.2.2 Antibacterial          

                                5.2.3 Antifungal

                                5.2.4 Antiviral   

                                5.2.5 Antiparasite           

                                5.2.6 others       

                                5.2.7 Y-o-Y Growth Analysis, By Target Organism               

                                5.2.8 Market Attractiveness Analysis, By Target Organism             

                                5.2.9 Market Share Analysis, By Target Organism              

                5.3 Infection type                           

                                5.3.1 Introduction           

                                5.3.2 Bacterial   

                                5.3.3 Viral           

                                5.3.4 Fungal       

                                5.3.5 parasitic   

                                5.3.6 others       

                                5.3.7 Y-o-Y Growth Analysis, By Infection type    

                                5.3.8 Market Attractiveness Analysis, By Infection type  

                                5.3.9 Market Share Analysis, By Infection Type   

                5.4 Distribution Channels                            

                                5.4.1 Hospitals  

                                5.4.2 Clinics        

                                5.4.3 Others      

                                5.4.4 Y-o-Y Growth Analysis, By Distribution Channels     

                                5.4.5 Market Attractiveness Analysis, By Distribution Channels   

                                5.4.6 Market Share Analysis, By Distribution Channels    

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Mode of Treatment

                                                6.1.3.3 By Target organism

                                                6.1.3.4 By Infection Type

                                                6.1.3.5 By Distribution Channels

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Mode of Treatment

                                                6.1.4.3 By Target organism

                                                6.1.4.4 By Infection Type

                                                6.1.4.5 By Distribution Channels

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Mode of Treatment

                                                6.1.5.3 By Target organism

                                                6.1.5.4 By Infection Type

                                                6.1.5.5 By Distribution Channels

                6.2 U.K                

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 F. Hoffmann-La Roche                           

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Gilead Sciences                         

                8.3 GlaxoSmithKline                      

                8.4 Johnson & Johnson                 

                8.5 Merck & Co                

                8.6 Pfizer                            

                8.7 Achillion Pharmaceuticals                    

                8.8 Novartis                       

                8.9 Abbvie                         

                8.10 Astellas Pharma                     

                8.11 AstraZeneca                            

                8.12 Auritec Pharmaceuticals                     

                8.13 Bayer                          

                8.14 Bristol-Myers Squibb                           

                8.15 Chimerix Pharmaceuticals                 

                8.16 Cubist                         

                8.17 Eli Lilly                        

                8.18 Isis Pharmaceuticals                             

                8.19 pSivida                       

                8.20 Sanofi                         

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Infectious Disease Therapeutics Market, By Mode of treatment, From 2021 to 2026 (USD Billion)
  2. Europe Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  3. Europe vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  4. Europe Infectious Disease Therapeutics Market, By Target Organism, From 2021 to 2026 (USD Billion)
  5. Europe Antibacterial Market, By Region, From 2021 to 2026 (USD Billion)
  6. Europe Antifungal Market, By Region, From 2021 to 2026 (USD Billion)
  7. Europe Antiviral Market, By Region, From 2021 to 2026 (USD Billion)
  8. Europe Antiparasite Market, By Region, From 2021 to 2026 (USD Billion)
  9. Europe Infectious Disease Therapeutics Market, By Infection Type, From 2021 to 2026 (USD Billion)
  10. Europe Bacterial Market, By Region, From 2021 to 2026 (USD Billion)
  11. Europe Viral Market, By Region, From 2021 to 2026 (USD Billion)
  12. Europe Fungal Market, By Region, From 2021 to 2026 (USD Billion)
  13. Europe Parasitic Market, By Region, From 2021 to 2026 (USD Billion)
  14. Europe Infectious Disease Therapeutics Market, By Distribution Channels, From 2021 to 2026 (USD Billion)
  15. Europe Hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  16. Europe Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  17. U.K. Infectious Disease Therapeutics Market, By Mode of treatment, From 2021 to 2026 (USD Billion)
  18. U.K. Infectious Disease Therapeutics Market, By Target Organism, From 2021 to 2026 (USD Billion)
  19. U.K. Infectious Disease Therapeutics Market, By Infection Type, From 2021 to 2026 (USD Billion)
  20. U.K. Infectious Disease Therapeutics Market, By Distribution Channels, From 2021 to 2026 (USD Billion)
  21. Germany Infectious Disease Therapeutics Market, By Mode of treatment, From 2021 to 2026 (USD Billion)
  22. Germany Infectious Disease Therapeutics Market, By Target Organism, From 2021 to 2026 (USD Billion)
  23. Germany Infectious Disease Therapeutics Market, By Infection Type, From 2021 to 2026 (USD Billion)
  24. Germany Infectious Disease Therapeutics Market, By Distribution Channels, From 2021 to 2026 (USD Billion)
  25. France Infectious Disease Therapeutics Market, By Mode of treatment, From 2021 to 2026 (USD Billion)
  26. France Infectious Disease Therapeutics Market, By Target Organism, From 2021 to 2026 (USD Billion)
  27. France Infectious Disease Therapeutics Market, By Infection Type, From 2021 to 2026 (USD Billion)
  28. France Infectious Disease Therapeutics Market, By Distribution Channels, From 2021 to 2026 (USD Billion)
  29. Italy Infectious Disease Therapeutics Market, By Mode of treatment, From 2021 to 2026 (USD Billion)
  30. Italy Infectious Disease Therapeutics Market, By Target Organism, From 2021 to 2026 (USD Billion)
  31. Italy Infectious Disease Therapeutics Market, By Infection Type, From 2021 to 2026 (USD Billion)
  32. Italy Infectious Disease Therapeutics Market, By Distribution Channels, From 2021 to 2026 (USD Billion)
  33. Spain Infectious Disease Therapeutics Market, By Mode of treatment, From 2021 to 2026 (USD Billion)
  34. Spain Infectious Disease Therapeutics Market, By Target Organism, From 2021 to 2026 (USD Billion)
  35. Spain Infectious Disease Therapeutics Market, By Infection Type, From 2021 to 2026 (USD Billion)
  36. Spain Infectious Disease Therapeutics Market, By Distribution Channels, From 2021 to 2026 (USD Billion)
  37. Europe Infectious disease Therapeutics Market, By Drugs, From 2021 to 2026 (USD Billion)
  38. Europe Oral Administration Market, By Region, From 2021 to 2026 (USD Billion)
  39. Europe Topical Market, By Region, From 2021 to 2026 (USD Billion)
  40. Europe Injections Market, By Region, From 2021 to 2026 (USD Billion)
  41. U.K. Infectious disease Therapeutics Market, By Drugs, From 2021 to 2026 (USD Billion)
  42. Germany Infectious disease Therapeutics Market, By Drugs, From 2021 to 2026 (USD Billion)
  43. France Infectious disease Therapeutics Market, By Drugs, From 2021 to 2026 (USD Billion)
  44. Italy Infectious disease Therapeutics Market, By Drugs, From 2021 to 2026 (USD Billion)
  45. Spain Infectious disease Therapeutics Market, By Drugs, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample